Population pharmacokinetic modeling of plasma and intracellular Ribavirin concentrations in patients with chronic hepatitis C virus infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2179-2188

  Wu, Liviawati S ^a   Rower, Joseph E ^b   Burton, James R ^c   Anderson, Peter L ^b   Hammond, Kyle P ^b   Baouchi Mokrane, Fafa ^d   Everson, Gregory T ^c   Urban, Thomas J ^e   D'Argenio, David Z ^a   Kiser, Jennifer J ^b  

^a University of Southern California   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DENVER HEALTH MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CREATININE; INOSINE TRIPHOSPHATE; PEGINTERFERON ALPHA2A; RIBAVIRIN; RIBAVIRIN DERIVATIVE; RIBAVIRIN DIPHOSPHATE; RIBAVIRIN MONOPHOSPHATE; RIBAVIRIN TRIPHOSPHATE; TELAPREVIR; UNCLASSIFIED DRUG; OLIGOPEPTIDE;

ABSORPTION RATE CONSTANT; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; COVARIANCE; CREATININE CLEARANCE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE; FEMALE; GENETIC ANALYSIS; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR MEMBRANE; MALE; MIDDLE AGED; OPEN STUDY; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOLOGICAL PARAMETERS; PLASMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUME OF DISTRIBUTION; BLOOD; GENETICS; HALF LIFE TIME; HEPATITIS C, CHRONIC; LIVER FUNCTION TEST; METABOLISM; PHOSPHORYLATION; POPULATION; SEXUAL DEVELOPMENT; STATISTICAL MODEL;

ADULT; ANTIVIRAL AGENTS; BODY WEIGHT; ERYTHROCYTES; FEMALE; HALF-LIFE; HEPATITIS C, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OLIGOPEPTIDES; PHOSPHORYLATION; POPULATION; RIBAVIRIN; SEX CHARACTERISTICS;

EID: 84928891908     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04618-14     Document Type: Article

References (49)

1. Witkowski JT, Robins RK, Sidwell RW, Simon LN. 1972. Design, synthesis, and broad spectrum antiviral activity of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 15:1150-1154. http://dx.doi.org/10.1021/jm00281a0142.
2. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706. http://dx.doi.org/10.1126/science.177.4050.705.
3. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. 2013. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310:804-811. http://dx.doi.org/10.1001/jama .2013.109309.
4. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603. http://dx.doi.org/10.1056/NEJMoa1315722.
5. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hezode C, Esteban R, VALENCE Investigators. 2014. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:1993-2001. http://dx.doi.org/10.1056/NEJMoa1316145.
6. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, PEARL-III Study, PEARL-IV Study. 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983-1992. http://dx.doi.org/10.1056/NEJMoa1402338.
7. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, Hutchison JG, Stedman CA. 2014. ELECTRON-2 (ledipasvir + sofosbuvir ± ribavirin). Abstr 49th Annu Meet Eur Assoc Study Liver (EASL), Abstract: O46.
8. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. 2008. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 28:1332-1343. http://dx.doi.org/10.1111/j.1478-3231.2008.01896.x.
9. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. 2000. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22:555-565.
10. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. 2002. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 24:701-708. http://dx.doi.org/10.1097/00007691-200212000-00004.
11. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 43:2451-2456.
12. Wu JZ, Larson G, Walker H, Shim JH, Hong Z. 2005. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 49:2164-2171. http://dx.doi.org/10.1128/AAC.49.6.2164-2171.2005.
13. Page T, Connor JD. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 22:379-383. http://dx.doi.org/10.1016/0020-711X(90)90140-X.
14. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:997-1004. http://dx.doi.org/10.1053/he.2000.5789.
15. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. 2004. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 11:84-87. http://dx.doi.org/10.1046/j.1365-2893.2003.00475.x.
16. Rendń AL, Núñez M, Romero M, Barreiro P, Martín-Carbonero L, García-Samaniego J, Jiménez-Nácher I, González-Lahoz J, Soriano V. 2005. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 39:401-405. http://dx.doi.org/10.1097/01.qai.0000170034.90438.68.
17. Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, Kohda Y. 2004. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2:337-339. http://dx.doi.org/10.1016/S1542-3565(04)00064-3.
18. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Kohda Y. 2006. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 34:23-27. http://dx.doi.org/10.1016/j.hepres.2005.10.003.
19. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. 2010. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408. http://dx.doi.org/10.1038/nature08825.
20. Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, Anderson PL. 2011. Determination of nucleoside analog mono-, di-, and triphosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharma Biomed Anal 56:390-401. http://dx.doi.org/10.1016/j.jpba.2011.05.039.
21. Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng JH, Kiser JJ. 17 December 2014, posting date. Measurement of intracellular ribavirin mono-, di-and triphosphate using solid phase extraction and LC-MS/MS quantification. J Chromatogr B Analyt Technol Biomed Life Sci http://dx.doi.org/10.1016/j.jchromb.2014.11.032.
22. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
23. Ahn JE, Karlsson MO, Dunne A, Ludden TM. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokin Pharmacodyn 35:401-421. http://dx.doi.org/10.1007/s10928-008-9094-4.
24. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. 2004. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 43:140-146. http://dx.doi.org/10.1053/j.ajkd.2003.09.019.
25. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. 2012. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J 14:571-580. http://dx.doi.org/10.1208/s12248-012-9368-z.
26. Glue P. 1999. The clinical pharmacology of ribavirin. Semin Liver Dis 19(Suppl 1):17-24.
27. Schering-Plough Corporation. 1998. Ribavirin. Schering-Plough Corporation, Kenilworth, NJ.
28. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM. 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 46: 563-570.
29. Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop NE, Jr. 1991. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 50:442-449. http://dx.doi.org/10.1038/clpt.1991.162.
30. Hoffmann-La Roche Inc. 2013. Copegus package insert. Hoffmann-La Roche Inc., Nutley, NJ.
31. Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, Roberts RB. 1987. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 41:546-555. http://dx.doi.org/10.1038/clpt.1987.70.
32. Paroni R, Del Puppo M, Borghi C, Sirtori CR, Galli Kienle M. 1989. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 27:302-307.
33. Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. 2012. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 17:1211-1221. http://dx.doi.org/10.3851/IMP2356.
34. Fukuda K, Imai Y, Hiramatsu N, Irishio K, Igura T, Sawai Y, Kogita S, Makino Y, Mizumoto R, Matsumoto Y, Nakahara M, Zushi S, Kajiwara N, Oze T, Kawata S, Hayashi N, Takehara T. 7 January 2014, posting date. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res http://dx.doi.org/10.1111/hepr.12229.
35. Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. 2013. A pilot study of tripletherapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 85:1746-1753.
36. Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. 2014. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 21:341-347. http://dx.doi.org/10.1111/jvh.12162.
37. Mauss S, Hueppe D, Alshuth U. 2014. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 59:46-48. http://dx.doi.org/10.1002/hep.26602.
38. Kunze A, Huwyler J, Camenisch G, Gutmann H. 2012. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 84:1096-1102. http://dx.doi.org/10.1016/j.bcp.2012.07.032.
39. Fujita Y, Noguchi K, Suzuki T, Katayama K, Sugimoto Y. 2013. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res Notes 6:445. http://dx.doi.org/10.1186/1756-0500-6-445.
40. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitisCvirus infection.NEngl J Med 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
41. Smee DF, Matthews TR. 1986. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother 30:117-121. http://dx.doi.org/10.1128/AAC.30.1.117.
42. Jarvis SM, Thorn JA, Glue P. 1998. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 123:1587-1592. http://dx.doi.org/10.1038/sj.bjp.0701775.
43. Patil SD, Ngo LY, Glue P, Unadkat JD. 1998. Intestinal absorption of ribavirin is preferentially mediated by the Na-nucleoside purine (N1) transporter. Pharm Res 15:950-952. http://dx.doi.org/10.1023/A:101194 5103455.
44. Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. 2007. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 557:1-8. http://dx.doi.org/10.1016/j.ejphar.2006.10.062.
45. Willis RC, Carson DA, Seegmiller JE. 1978. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A 75:3042-3044. http://dx.doi.org/10.1073/pnas.75.7 .3042.
46. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ. 2006. Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother 50:2686-2694. http://dx.doi.org/10.1128/AAC.01637-05.
47. Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB. 2011. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 140:1314-1321. http://dx.doi.org/10.1053/j.gastro.2010.12.038.
48. Catlin DH, Smith RA, Samuels AI. 1980. 14C-Ribavirin: distribution and pharmacokinetic studies in rats, baboons and man, p 83-98. In Smith RA, Kirkpatrick W (ed), Ribavirin: a broad spectrum antiviral agent. Academic Press, New York, NY.
49. Krishnan SM, Dixit NM. 2011. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 7:e1001072. http://dx.doi.org/10.1371/journal.pcbi.1001072.